These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 25200545)

  • 1. Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis.
    Warnke C; Adams O; Kieseier B
    JAMA Neurol; 2014 Sep; 71(9):1192. PubMed ID: 25200545
    [No Abstract]   [Full Text] [Related]  

  • 2. Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis--reply.
    Frohman EM; Douek D; Major EO
    JAMA Neurol; 2014 Sep; 71(9):1192-3. PubMed ID: 25200546
    [No Abstract]   [Full Text] [Related]  

  • 3. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.
    Frohman EM; Monaco MC; Remington G; Ryschkewitsch C; Jensen PN; Johnson K; Perkins M; Liebner J; Greenberg B; Monson N; Frohman TC; Douek D; Major EO
    JAMA Neurol; 2014 May; 71(5):596-602. PubMed ID: 24664166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab.
    Lin J; Bettin P; Lee JK; Ho JK; Sadiq SA
    J Neuroimmunol; 2013 Aug; 261(1-2):123-8. PubMed ID: 23800458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrepant findings in immune responses to JC virus in patients receiving natalizumab.
    Tan CS; Chen Y; Viscidi RP; Kinkel RP; Stein MC; Koralnik IJ
    Lancet Neurol; 2010 Jun; 9(6):565-6; author reply 566-7. PubMed ID: 20494320
    [No Abstract]   [Full Text] [Related]  

  • 6. High discontinuation rate of natalizumab in JC virus seropositive patients due to significant anxiety and safety feelings.
    Alroughani R
    Mult Scler; 2014 Oct; 20(12):1667-8. PubMed ID: 24619935
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of prolonged natalizumab treatment on anxiety and safety in JC virus-seropositive MS patients; a follow-up study.
    van Rossum JA; Vennegoor A; Killestein J
    Mult Scler; 2014 Oct; 20(12):1668-9. PubMed ID: 25112817
    [No Abstract]   [Full Text] [Related]  

  • 8. Reemergence of PML in natalizumab-treated patients--new cases, same concerns.
    Major EO
    N Engl J Med; 2009 Sep; 361(11):1041-3. PubMed ID: 19741226
    [No Abstract]   [Full Text] [Related]  

  • 9. About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors.
    Vuaillat C; Androdias G; Davoust N; Nataf S
    Blood; 2008 Jul; 112(1):208-9; author reply 209-10. PubMed ID: 18574042
    [No Abstract]   [Full Text] [Related]  

  • 10. Low JC virus antibody index during natalizumab treatment less safe than assumed?
    Killestein J; Wattjes MP
    Mult Scler; 2015 Dec; 21(14):1753-4. PubMed ID: 26449744
    [No Abstract]   [Full Text] [Related]  

  • 11. More on JC viremia in natalizumab-treated patients with multiple sclerosis.
    Subramanyam M; Belachew S; Compton T
    N Engl J Med; 2013 Sep; 369(13):1279-80. PubMed ID: 24066762
    [No Abstract]   [Full Text] [Related]  

  • 12. More on JC viremia in natalizumab-treated patients with multiple sclerosis.
    Major EO; Frohman E; Douek D
    N Engl J Med; 2013 Sep; 369(13):1280. PubMed ID: 24066761
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.
    van Rossum JA; Vennegoor A; Balk L; Uitdehaag BM; Polman CH; Killestein J
    Mult Scler; 2014 Jan; 20(1):108-11. PubMed ID: 23828867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
    Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
    Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.
    Bozic C; Richman S; Plavina T; Natarajan A; Scanlon JV; Subramanyam M; Sandrock A; Bloomgren G
    Ann Neurol; 2011 Nov; 70(5):742-50. PubMed ID: 22162056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab treatment for multiple sclerosis.
    Ferreira ML
    Arq Neuropsiquiatr; 2014 Dec; 72(12):911-2. PubMed ID: 25517640
    [No Abstract]   [Full Text] [Related]  

  • 17. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors.
    Saure C; Warnke C; Zohren F; Schroeder T; Bruns I; Cadeddu RP; Weigelt C; Fischer U; Kobbe G; Hartung HP; Adams O; Kieseier BC; Haas R
    Arch Neurol; 2011 Nov; 68(11):1428-31. PubMed ID: 22084125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-JC Virus Antibodies in a Large German Natalizumab-Treated MS Cohort.
    Zahednasab H
    Neurology; 2012 Nov; 79(19):2010; author reply 2010-1. PubMed ID: 23128444
    [No Abstract]   [Full Text] [Related]  

  • 19. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
    Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
    Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
    Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.